Research programme: BET bromodomain inhibitors - Nuevolution

Drug Profile

Research programme: BET bromodomain inhibitors - Nuevolution

Alternative Names: NUE 7770; NUE007770-7

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nuevolution
  • Class Small molecules
  • Mechanism of Action BRD1 protein inhibitors; Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Arthritis; Atopic dermatitis; Idiopathic pulmonary fibrosis; Inflammation; Psoriasis; Systemic lupus erythematosus

Most Recent Events

  • 27 Nov 2017 Preclinical trials in Atopic dermatitis in Denmark (unspecified route)
  • 27 Nov 2017 Preclinical trials in Psoriasis in Denmark (unspecified route)
  • 19 Jun 2017 Positive pharmacodynamics data from a preclinical study in Systemic lupus erythematosus released by Nuevolution
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top